{"drugs":["Gildess FE 1.5\/30","Gildess FE 1\/20","Larin FE 1.5\/30","Larin FE 1\/20","Loestrin 24 Fe","Minastrin 24 Fe","Norethindrone acetate\/Ethinyl estradiol and Ferrous fumarate","Tilia Fe","Tri-Legest FE 28"],"mono":[{"id":"930564-s-0","title":"Generic Names","mono":"Norethindrone acetate\/Ethinyl estradiol and Ferrous fumarate"},{"id":"930564-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930564-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>(Minastrin(TM) 24 Fe chewable tablets) Switching from a progestin-only pill:<\/b> Start the first dose on the day of next scheduled dose and use nonhormonal backup method of contraception for the first 7 days of therapy; if switching from an implantable contraceptive or injection, start the first dose on day next injection is due or day implant is removed; if switching from an intrauterine device (IUD), backup contraception may be needed depending on the timing of removal; if switching from another combination hormonal method (pill, vaginal ring, patch), start the first dose on the day of next scheduled dose of the previous birth control method.<\/li><li>(Loestrin(R) 24 Fe) May switch from a 21-day regimen of oral contraceptive, transdermal patch, or a vaginal ring after completion of 21-day regimen and waiting 7 days after the last tablet, patch, or ring; may switch from a 28-day regimen of oral contraceptive by starting first dose on the day of next scheduled dose without skipping days; may switch from progestin-only pill at any time; may switch from implants the same day as implant removed; may switch from injections the day next injection is due<\/li><li>(Loestrin(R) Fe) May switch from a 21-day regimen of oral contraceptive after completion of tablets and waiting 7 days; may switch from a 28-day regimen of oral contraceptive by starting first dose on the day of next scheduled dose without skipping days<\/li><li><b>Contraception:<\/b> Loestrin(R) Fe 1\/20, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package: 1 active tablet daily for 21 consecutive days, then 1 brown tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Loestrin(R) Fe 1.5\/30: 1 tablet ORALLY daily at the same time of day, at intervals not more than 24 hours, and in the order of the package; 1 active tablet daily for 21 consecutive days, then 1 nonhormonal tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Loestrin(R) 24 Fe, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package: 1 active tablet daily for 24 consecutive days, then 1 nonhormonal tablet daily for 4 days; repeat cycle<\/li><li><b>Contraception:<\/b> Minastrin(TM) 24 Fe chewable tablets, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package, swallowed whole or chewed and swallowed, followed by 8 ounces of water: 1  active  tablet daily for 24 consecutive days, then 1 nonhormonal tablet daily for 4 days; repeat cycle<\/li><li><b>Contraception:<\/b> Begin therapy on the first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 to 6 weeks postpartum in nonlactating women (Loestrin(R) 24 Fe; Minastrin(TM) 24 Fe chewable tablets; Loestrin(R) Fe) or 4 weeks after a second-trimester abortion (Minastrin(TM) 24 Fe chewable tablets); a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if postpartum woman has not started a menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated immediately following a first-trimester abortion or miscarriage.<\/li><\/ul>"},"1":{"id":"930564-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy have not been established before menarche.<\/li><li><b>(Minastrin(TM) 24 Fe chewable tablets) Switching from a progestin-only pill:<\/b> Start the first dose on the day of next scheduled dose and use nonhormonal backup method of contraception for the first 7 days of therapy; if switching from an implantable contraceptive or injection, start the first dose on day next injection is due or day implant is removed; if switching from an intrauterine device (IUD), backup contraception may be needed depending on the timing of removal; if switching from another combination hormonal method (pill, vaginal ring, patch), start the first dose on the day of next scheduled dose of the previous birth control method.<\/li><li>(Loestrin(R) 24 Fe) May switch from a 21-day regimen of oral contraceptive, transdermal patch, or a vaginal ring after completion of 21-day regimen and waiting 7 days after the last tablet, patch, or ring; may switch from a 28-day regimen of oral contraceptive by starting first dose on the day of next scheduled dose without skipping days; may switch from progestin-only pill at any time; may switch from implants the same day as implant removed; may switch from injections the day next injection is due<\/li><li>(Loestrin(R) Fe) May switch from a 21-day regimen of oral contraceptive after completion of tablets and waiting 7 days; may switch from a 28-day regimen of oral contraceptive by starting first dose on the day of next scheduled dose without skipping days<\/li><li><b>Contraception:<\/b> After menarche: Loestrin(R) Fe 1\/20, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package: 1 active tablet daily for 21 consecutive days, then 1 brown tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> After menarche: Loestrin(R) Fe 1.5\/30: 1 tablet ORALLY daily at the same time of day, at intervals not more than 24 hours, and in the order of the package; 1 active tablet daily for 21 consecutive days, then 1 nonhormonal tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> After menarche: Loestrin(R) 24 Fe, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package: 1 active tablet daily for 24 consecutive days, then 1 nonhormonal tablet daily for 4 days; repeat cycle<\/li><li><b>Contraception:<\/b> After menarche: Minastrin(TM) 24 Fe chewable tablets, 1 tablet ORALLY daily at the same time of day at intervals not more than 24 hours in the order of the package, swallowed whole or chewed and swallowed, followed by 8 ounces of water: 1  active  tablet daily for 24 consecutive days, then 1 nonhormonal tablet daily for 4 days; repeat cycle<\/li><li><b>Contraception:<\/b> Begin therapy on the first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 to 6 weeks postpartum in nonlactating women (Loestrin(R) 24 Fe; Minastrin(TM) 24 Fe chewable tablets; Loestrin(R) Fe) or 4 weeks after a second-trimester abortion (Minastrin(TM) 24 Fe chewable tablets); a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if postpartum woman has not started a menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated immediately following a first-trimester abortion or miscarriage.<\/li><\/ul>"},"3":{"id":"930564-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},{"id":"930564-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet, Chewable; Tablet)<\/b><br\/>Combination oral contraceptives should not be used by women over the age of 35 years who smoke. Smoking cigarettes increases the risk of serious cardiovascular events due to combination oral contraceptive use. Risk is increased age, especially women older than 35 years, and with number of cigarettes smoked.<br\/>"},{"id":"930564-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930564-s-3-9","title":"Contraindications","mono":"<ul><li>Benign or malignant hepatic tumors<\/li><li>Cerebrovascular disease<\/li><li>Cholestatic jaundice of pregnancy or jaundice with prior use<\/li><li>Cigarette smoking and older than 35 years<\/li><li>Coronary artery disease<\/li><li>Current or past history of breast cancer or other estrogen- or progestin-sensitive cancer;<\/li><li>Current or past history of DVT or pulmonary embolism<\/li><li>Diabetes mellitus with vascular disease<\/li><li>Headaches with focal neurological symptoms, migraine headaches with aura, and any woman older than 35 with migraine headaches<\/li><li>Hepatic disease<\/li><li>Inherited or acquired hypercoagulopathies<\/li><li>Major surgery with prolonged mobilization; discontinue use 4 weeks before and through 2 weeks after procedure<\/li><li>Pregnancy<\/li><li>Thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation)<\/li><li>Uncontrolled hypertension<\/li><li>Undiagnosed abnormal uterine bleeding<\/li><\/ul>"},{"id":"930564-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Hypertension may occur, especially in older women with extended duration of use<\/li><li>Dermatologic:<\/li><li>-- Chloasma may occur, especially with history of chloasma gravidarum; avoid exposure to sunlight or ultraviolet light<\/li><li>Endocrine and Metabolic:<\/li><li>-- Diabetes (including prediabetic women); glucose tolerance may be impaired; monitoring recommended<\/li><li>-- Uncontrolled dyslipidemia; consider alternative contraception<\/li><li>Gastrointestinal:<\/li><li>-- New-onset or an exacerbation of gallbladder disease may occur<\/li><li>-- History of cholestasis related to pregnancy or hormonal contraceptive use; increased risk for recurrence<\/li><li>Hematologic:<\/li><li>-- Venous and arterial thrombotic events, such as DVT, pulmonary embolism, stroke, and myocardial infarction, may occur; discontinue use<\/li><li>Hepatic:<\/li><li>-- Hepatic adenoma or hepatocellular carcinoma may rarely occur<\/li><li>-- Jaundice may occur; discontinue use<\/li><li>Neurologic:<\/li><li>-- New-onset headaches that are recurrent, persistent, or severe; evaluate and discontinue use if necessary<\/li><li>-- Migraine headaches that increase in frequency or severity; evaluate and discontinue use if necessary<\/li><li>Ocular:<\/li><li>-- Retinal vein thrombosis may occur; discontinue use if unexplained ocular symptoms emerge (eg, loss of vision, diplopia, proptosis, papilledema, retinal vascular lesions)<\/li><li>Psychiatric:<\/li><li>-- Depression may be exacerbated; discontinuation may be warranted<\/li><li>Reproductive:<\/li><li>-- Vaginal bleeding abnormalities, including breakthrough bleeding and spotting, may occur<\/li><li>-- Amenorrhea or oligomenorrhea may occur after discontinuation, especially if preexisting<\/li><li>Other:<\/li><li>-- Postpartum period; increased risk of thromboembolism; do not initiate therapy earlier than 4 weeks after delivery<\/li><li>-- Hereditary angioedema; may induce or exacerbate symptoms<\/li><\/ul>"},{"id":"930564-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"930564-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"930564-s-4","title":"Drug Interactions","sub":[{"id":"930564-s-4-13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"930564-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eltrombopag (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"930564-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Carbidopa (probable)<\/li><li>Cefdinir (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Demeclocycline (probable)<\/li><li>Dolutegravir (established)<\/li><li>Doxycycline (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Gatifloxacin (probable)<\/li><li>Ginseng (probable)<\/li><li>Grepafloxacin (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Levodopa (probable)<\/li><li>Levofloxacin (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Licorice (probable)<\/li><li>Lomefloxacin (probable)<\/li><li>Methyldopa (probable)<\/li><li>Minocycline (probable)<\/li><li>Modafinil (probable)<\/li><li>Moxifloxacin (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Norfloxacin (probable)<\/li><li>Ofloxacin (probable)<\/li><li>Omeprazole (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Penicillamine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Temafloxacin (probable)<\/li><li>Tetracycline (probable)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Trovafloxacin Mesylate (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><li>Zinc (established)<\/li><\/ul>"}]},{"id":"930564-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Acne (2.7%)<\/li><li><b>Endocrine metabolic:<\/b>Abnormal weight gain (2%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (4.6%), Vomiting (2% to 6%)<\/li><li><b>Neurologic:<\/b>Headache (6.3%)<\/li><li><b>Psychiatric:<\/b>Mood swings (2.2%)<\/li><li><b>Reproductive:<\/b>Abnormal cervical smear (3.1%), Amenorrhea (22% to 36%), Bacterial vaginosis (3.1%), Breast tenderness (3.4%), Candida vaginitis (6.1%), Intermenstrual bleeding - irregular (24 to 35%), Menstrual cramp (4.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Arterial thrombosis, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Adenoma of liver, Liver carcinoma<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><\/ul>"},{"id":"930564-s-6","title":"Drug Name Info","sub":{"0":{"id":"930564-s-6-17","title":"US Trade Names","mono":"<ul><li>Tilia Fe<\/li><li>Gildess FE 1\/20<\/li><li>Gildess FE 1.5\/30<\/li><li>Tri-Legest FE 28<\/li><li>Loestrin 24 Fe<\/li><li>Minastrin 24 Fe<\/li><li>Larin FE 1.5\/30<\/li><li>Larin FE 1\/20<\/li><\/ul>"},"2":{"id":"930564-s-6-19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Estrogen\/Progestin Combination<\/li><li>Hormonal Contraceptive<\/li><li>Monophasic Contraceptive Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"930564-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930564-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"930564-s-7","title":"Mechanism Of Action","mono":"Combination estrogen and progestin oral contraceptives act by suppressing gonadotrophins, thereby inhibiting ovulation. Additional mechanisms of action of combination oral contraceptives include changes in the cervical mucus thus inhibiting sperm penetration and entry into the uterus, and endometrial lining changes that may prevent implantation.<br\/>"},{"id":"930564-s-8","title":"Pharmacokinetics","sub":[{"id":"930564-s-8-23","title":"Absorption","mono":"<ul><li>Ethinyl estradiol, Tmax, Oral: 1.7 hours<\/li><li>Norethindrone acetate, Tmax, Oral: 1.3 hours<\/li><li>Ethinyl estradiol, Bioavailability,, Oral: 43%<\/li><li>Norethindrone acetate, Bioavailability, Oral: approximately 64%<\/li><li>Ethinyl estradiol, Effects of food, Minastrin 24 Fe(TM): 34% decreased Cmax, extent of absorption unaffected; Loestrin 24 Fe(R): 30% decrease in Cmax; extent of absorption not decreased<\/li><li>Norethindrone acetate, Effects of food, Minastrin 24 Fe(TM): 35% decreased Cmax, extent of absorption unaffected; Loestrin 24 Fe(R): 11% decreased Cmax, 27% increased extent of absorption<\/li><\/ul>"},{"id":"930564-s-8-24","title":"Distribution","mono":"<ul><li>Ethinyl estradiol, Protein binding, albumin: greater than 95%<\/li><li>Norethindrone, Protein binding, albumin and sex hormone binding globulin: greater than 95%<\/li><li>Ethinyl estradiol and norethindrone, Vd: 2 to 4 L\/kg<\/li><\/ul>"},{"id":"930564-s-8-25","title":"Metabolism","mono":"<ul><li>Ethinyl estradiol, Liver: extensive via oxidation by CYP3A4 and conjugation<\/li><li>Ethinyl Estradiol, Gastrointestinal mucosa: portion of first-pass metabolism<\/li><li>Norethindrone acetate, Liver: deacetylated to norethindrone and then metabolized via reduction and sulfate and glucuronide conjugation<\/li><li>Ethinyl estradiol: 2-hydroxy ethinyl estradiol, unknown activity; sulfate (major) and glucuronide conjugates, unknown activity<\/li><li>Norethindrone, Sulfates and glucuronide conjugates (major): activity unknown<\/li><li>Ethinyl estradiol: CYP3A4 substrate<\/li><\/ul>"},{"id":"930564-s-8-26","title":"Excretion","mono":"<ul><li>Ethinyl estradiol and norethindrone acetate, Fecal excretion: primarily as metabolites<\/li><li>Ethinyl estradiol and norethindrone acetate, Renal excretion: primarily as metabolites<\/li><li>Ethinyl estradiol and norethindrone acetate, Total body clearance: approximately 0.4 L\/hr\/kg<\/li><\/ul>"},{"id":"930564-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Ethinyl estradiol, 14.5 hours<\/li><li>Norethindrone acetate, 8.4 hours<\/li><\/ul>"}]},{"id":"930564-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Take exactly as directed at the same time every day in the order on the blister pack.<\/li><li>Do not skip doses or take at intervals exceeding 24 hours.<\/li><li>(Loestrin(R) 24 Fe, Minastrin(TM) 24 Fe chewable tablets) May take with or without food<\/li><li>(Minastrin(TM) 24 Fe chewable tablets) May be chewed and swallowed or swallowed whole; drink a full 8-ounce glass of water after swallowing tablets<\/li><li>(Loestrin(R) Fe) Take with a meal or at bedtime<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 1 missed active dose, take as soon as remembered; may take 2 tablets in 1 day; nonhormonal backup contraception is not necessary.<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 2 consecutive missed active doses in week 1 or 2, take 2 tablets on the day remembered and 2 tablets the next day; nonhormonal backup contraception should be used until the patient has taken an active dose for 7 consecutive days.<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 2 consecutive missed active doses in week 3 or 4, or with 3 or more consecutive missed active doses at any time, discard the rest of the pack and start a new pack that same day; for Sunday starters, continue the same pack until Sunday, and then discard the remainder and start a new pack; nonhormonal backup contraception should be used until the patient has taken an active dose for 7 consecutive days.<\/li><li>Missed doses: With any missed nonhormonal doses in week 4, throw away missed pills and continue taking remaining pills to finish the pack; nonhormonal backup contraception is not necessary.<\/li><\/ul>"},{"id":"930564-s-10","title":"Monitoring","mono":"<ul><li>signs and symptoms of glucose intolerance in prediabetic and diabetic women<\/li><li>history and physical exam; at least annually, including special reference to blood pressure, breasts, abdomen and pelvic organs (including cervical cytology and relevant laboratory tests)<\/li><li>lipid levels in women receiving treatment for hyperlipidemia<\/li><li>blood pressure in patients with history of hypertension  or hypertension-related diseases or renal disease<\/li><li>breast changes in patients with breast nodules or with a strong family history of breast cancer<\/li><li>fluid retention in patients with conditions potentially aggravated by fluid retention<\/li><li>depression recurrence in patients with history of depression<\/li><\/ul>"},{"id":"930564-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Gildess 24 Fe<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Gildess FE 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Gildess FE 1.5\/30<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 30 MCG,75 MG,1.5 MG<br\/><\/li><li><b>Junel Fe 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Junel Fe 1.5\/30<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 30 MCG,75 MG,1.5 MG<br\/><\/li><li><b>Junel Fe 24<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Larin Fe 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Larin Fe 1.5\/30<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 30 MCG,75 MG,1.5 MG<br\/><\/li><li><b>Loestrin 24 Fe<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Loestrin Fe 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Loestrin Fe 1.5\/30<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 30 MCG,75 MG,1.5 MG<br\/><\/li><li><b>Lomedia 24 Fe<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Microgestin Fe 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Microgestin Fe 1.5\/30<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 30 MCG,75 MG,1.5 MG<br\/><\/li><li><b>Minastrin 24 Fe<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><li><b>Tarina Fe 1\/20<\/b><br\/>KIT: (Ethinyl Estradiol - Norethindrone Acetate;Ferrous FumarateEthinyl Estradiol - Norethindrone Acetate;Ferrous Fumarate) 20 MCG,75 MG,1 MG<br\/><\/li><\/ul>"},{"id":"930564-s-12","title":"Toxicology","sub":[{"id":"930564-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>IRON<\/b><br\/>USES: Found primarily as a nutritional supplement in vitamins. Used for the treatment and prevention of iron-deficiency anemia. PHARMACOLOGY: Iron is required in the function of multiple essential protein and enzyme complexes including hemoglobin, myoglobin, and cytochromes. TOXICOLOGY: Iron is a general cellular poison and is directly corrosive to the GI mucosa. EPIDEMIOLOGY: Historically, a common poisoning which was one of the leading causes of pediatric toxicologic deaths. Exposure has been reduced in recent years with improved packaging, but still has the potential for significant morbidity and mortality. MILD TO MODERATE POISONING: Vomiting and diarrhea may occur within 6 hours of ingestion. SEVERE POISONING: Severe vomiting and diarrhea, lethargy, metabolic acidosis, shock, GI hemorrhage, coma, seizures, hepatotoxicity, and late onset GI strictures. PHASE I (0.5 to 2 hours) includes vomiting, hematemesis, abdominal pain, diarrhea, hematochezia, lethargy, shock, acidosis, and coagulopathy. Necrosis to the GI tract occurs from the direct effect of iron on GI mucosa. Severe gastrointestinal hemorrhagic necrosis with large losses of fluid and blood contribute to shock. PHASE II includes apparent recovery; continue to observe patient closely. PHASE III (2 to 12 hours after phase I) includes profound shock, severe acidosis, cyanosis, and fever. Increased total peripheral resistance, decreased plasma volume, hemoconcentration, decrease in total blood volume, hypotension, CNS depression, and metabolic acidosis have been demonstrated. PHASE IV (2 to 4 days) includes possible hepatotoxicity. Thought to be a direct action of iron on mitochondria. Monitor liver function tests and bilirubin. Acute lung injury may also occur. Phase V (days to weeks) includes GI scarring and strictures. GI obstruction secondary to gastric or pyloric scarring may occur due to corrosive effects of iron. Sustained-release preparations have resulted in small intestinal necrosis with resultant scarring and obstruction. Carbonyl iron (also referred to as &quot;iron carbonyl&quot;) appears to be less toxic than other iron formulations because of limited absorption. Please refer to the CARBONYL IRON management for further information. Case reports suggest that iron-dextran complex overdoses may be associated with high serum iron concentrations without evidence of a corresponding degree of clinical symptoms and signs of toxicity. Please refer to the IRON DEXTRAN management for further information. ADVERSE EFFECTS: GI upset, constipation.<br\/><\/li><li><b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/><\/li><\/ul>"},{"id":"930564-s-12-32","title":"Treatment","mono":"<ul><li><b>IRON <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Supportive care with intravenous fluid hydration is usually sufficient for mild poisonings. Activated charcoal is not effective for iron ingestions. Patients who are symptomatic should be observed for clinical deterioration and development of acidosis. Abdominal x-rays should be obtained as tablets are generally radiopaque. When large amounts of tablets are visible on radiograph, consider whole bowel irrigation. An iron concentration should be measured 4 to 6 hours after the initial ingestion and then repeated in 2 to 4 hours. Patients who develop metabolic acidosis or are clinically worsening with IV hydration should be treated with chelation. MANAGEMENT OF SEVERE TOXICITY: Chelation with deferoxamine is needed for patients with signs of severe poisoning including shock, acidosis, GI hemorrhage, and lethargy or coma. Consider chelation for serum iron concentrations greater than 500 mcg\/dL (a patient will usually have significant signs and symptoms of toxicity). Patients may need blood transfusions if they have significant GI hemorrhage.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal is not useful. Most patients have spontaneous vomiting. HOSPITAL: Activated charcoal does not adequately bind iron and is not useful. Studies have suggested that magnesium hydroxide antacids (5 mg magnesium hydroxide per gram of elemental iron ingested) decrease serum iron concentrations following a simulated overdose. Gastric lavage may be useful soon after ingestion in adults, but the nasogastric tubes used in children are not sufficiently large to remove tablets. In patients with large amounts of radiopaque tablets in the GI tract, whole bowel irrigation with polyethylene glycol should be considered. Endoscopic removal is another option for patients with a large number of tablets in the stomach.<\/li><li>Airway management: Patients who are comatose or with altered mental status may need mechanical respiratory support and orotracheal intubation.<\/li><li>Antidote: DEFEROXAMINE can be used to chelate iron and should be used when there are signs of severe poisoning including shock, acidosis, GI hemorrhage, and coma. Deferoxamine is administered intravenously at a rate of 15 mg\/kg\/hour; it can be titrated up to a rate of 40 mg\/kg\/hour for patients with severe poisoning. However, hypotension may occur with high dose deferoxamine infusion and the rate should be slowed if this occurs. Deferoxamine should be continued for 12 to 24 hours and then titrated off if the patient is clinically improving. If the patient worsens as the deferoxamine is titrated off, it should be restarted. Prolonged (greater than 24 hours) high dose infusion of deferoxamine has been associated with acute lung injury and should be avoided. Patients receiving deferoxamine chelation are at increased risk for Yersinia enterocolitica sepsis.<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Serial serum iron levels are indicated. Obtain a complete metabolic panel and complete blood count. Baseline arterial or venous blood gas in patients with severe toxicity. Obtain an abdominal radiograph to evaluate for retained tablets.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine.<\/li><li>Enhanced elimination procedure: Hemodialysis is not effective in removing iron, but may be necessary to remove deferoxamine-iron complexes in patients with renal insufficiency. Consider exchange transfusion in those patients with a serum iron exceeding 1000 mcg\/dL who clinically deteriorate despite supportive care and intravenous chelation therapy.<\/li><li>Patient disposition: HOME CRITERIA: Inadvertent ingestions of less than 40 mg\/kg of elemental iron in patients who have only mild GI symptoms (self limited vomiting or diarrhea) can be watched at home. OBSERVATION CRITERIA: Patients with more than mild symptoms, those who have ingested 40 mg\/kg or more, or patients with intentional ingestions should be sent to a healthcare facility for evaluation. ADMISSION CRITERIA: Patients who have hypotension, severe or worsening metabolic acidosis, GI hemorrhage, altered mental status, or a patient that requires chelation should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings and for recommendations on determining the need for chelation or whole bowel irrigation. Consult a gastroenterologist for endoscopic removal if many tablets persist in the stomach.<\/li><\/ul><\/li><li><b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul><\/li><\/ul>"},{"id":"930564-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>IRON<\/b><br\/>TOXICITY: Ingestion of less than 40 mg\/kg generally does not cause significant toxicity, although mild GI irritation may develop. Mild symptoms are likely to occur with peak iron concentrations greater than 300 mcg\/dL, while peak concentrations of more than 500 mcg\/dL generally causes severe symptoms. If the patient presents after peak concentrations have occurred, severe toxicity may be associated with lower iron concentrations. THERAPEUTIC DOSE: Daily doses for children with severe iron deficiency are generally 4 to 6 mg\/kg\/day. Normal serum iron levels generally range from 65 to 175 mcg\/dL. The percentage of elemental iron in ferrous gluconate is approximately 11%, ferrous sulfate 22%, and ferrous fumarate 33%.<br\/><\/li><li><b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested.<br\/><\/li><\/ul>"}]},{"id":"930564-s-13","title":"Clinical Teaching","mono":"<ul><li>Patients should not smoke during therapy, especially smokers over 35 years old, as this increases the risk for serious cardiovascular events.<\/li><li>This drug may cause headaches, breast tenderness, nausea, and increased weight.<\/li><li>Instruct patient to take one pill at the same time each day in the exact order noted on the packaging.<\/li><li>Advise patient that certain drugs may cause oral contraceptives to be less effective and backup contraception may be necessary. Consult healthcare professional prior to new drug use.<\/li><li>Tell patient what to do in the event of a missed pill. If the patient experiences amenorrhea, pregnancy should be ruled out.<\/li><\/ul>"}]}